Qiagen has partnered with US-based Inovio Pharmaceuticals to create a companion diagnostic to identify patients who are most likely to respond to the drugmaker’s new immunotherapy, VGX-3100.

VGX-3100 is a DNA-based therapeutic meant for the treatment of cervical dysplasia caused by human papillomavirus (HPV). The compound is currently undergoing two Phase III clinical trials.

If approved, VGX-3100 is expected to be the first therapy for HPV infection of the cervix as well as the first non-surgical treatment for precancerous cervical lesions caused by the virus.

The alliance will leverage Qiagen’s expertise in HPV-related molecular testing and cervical cancer.

Qiagen CEO Peer Schatz said: “We are pleased to support Inovio by developing a liquid biopsy-based companion diagnostic to identify patients who would benefit from VGX-3100, which has potential to make a dramatic difference in the detection of HPV infections and treatment of precancerous disease.

“This project is also a case study of a collaboration that started in the discovery phase, when Inovio selected Qiagen Genomic Services to work on the discovery of novel biomarkers that now contribute to the power of this unique molecular assay. The project progressed into development and Inovio now aims to make regulatory submissions for VGX-3100 in 2021.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Qiagen develops molecular diagnostics for screening targets linked to the risk and progression of cervical cancer. Its portfolio includes multiple tests for the cancer.

“A liquid biopsy-based companion diagnostic has potential to make a dramatic difference in the detection of HPV infections and treatment of precancerous disease.”

digene Hybrid Capture 2 High-Risk HPV DNA Test is intended for HPV screening, while QIAGEN’s careHPV Test is meant to help detect the cancer in low-resource regions.

In addition, the QIAsure Methylation Test differentiates patients’ risk for cervical cancer after a positive test for high-risk HPV. The company’s new QIAscreen HPV PCR Test is set to launch in the near future in Europe.

Last month, Qiagen launched a companion diagnostic called therascreen FGFR Kit to identify patients that are eligible for treatment with Janssen Biotech’s fibroblast growth factor receptor (FGFR) kinase inhibitor drug Balversa.